Compare Crispr Therapeutics AG (CRSP) vs Zeta Global Holdings Corp (ZETA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Zeta Global Holdings Corp — how do they compare? Crispr Therapeutics AG trades at $54 (market cap $5.22B), while Zeta Global Holdings Corp trades at $29.55 (market cap $7.17B). The key difference: Zeta Global Holdings Corp is the larger of the two by market cap, and Zeta Global Holdings Corp is trading nearer its 52-week high, Crispr Therapeutics AG nearer its low. Which is the better fit depends on your goals.
| CRSP | ZETA | |
|---|---|---|
Market Cap | $5.22B | $7.17B |
Sector | Health | Technology |
52-Week High | $76.78 | $29.15 |
52-Week Low | $44.34 | $14.55 |
Enterprise Value | $3.64B | $7.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $53.99, down 0.15% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a Q2 2026 EPS beat with a loss of $0.94 versus an expected $1.19 loss, driven by 151% YoY growth in CASGEVY sales to $76 million. Financials show deep losses with a net income margin of -4,101.26% in 2025, though cash flow improved to a net positive $49.30M. Recent news highlights strong analyst optimism and pipeline advancements.
Outlook remains speculative with high growth potential from gene-editing therapies like CASGEVY, but significant risks persist from ongoing losses and clinical trial outcomes. Wall Street consensus is bullish with a $82.67 price target, implying 53% upside, though investors face volatility from earnings misses and cash burn.
ZETA trades at $28.55, down 2.06% over 24 hours, with a bullish technical outlook from moving averages but overbought RSI signals. The stock shows strong revenue growth, with Q2 2026 revenue up 44% year-over-year to $443 million and 20 consecutive quarters of beating earnings expectations, though net income margins remain negative. Recent news highlights AI adoption and a partnership with Palantir as growth catalysts.
The outlook is positive due to robust revenue expansion and analyst consensus, but risks include high valuation multiples and execution challenges. With a consensus price target of $30.44 and 73% buy ratings, upside potential exists if profitability improves, though investors should monitor margin trends and competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Zeta Global Holdings Corp
Zeta Global is a leading data-driven marketing technology company that provides an omnichannel AI Marketing Cloud. By leveraging a proprietary data cloud of over 2.4 billion deterministic identities, it enables enterprise brands to acquire, grow, and retain customers through predictive intelligence and automated, agentic workflows.
Read more on ZETA →
